• Cutting-Edge
    Clinical Trials

Every therapy, drug or approach that is in place today to treat cancer had its start in a clinical trial. American Oncology Partner practices bring innovative treatment options to patients, close to home. By partnering with Sarah Cannon, a global leader in offering community-based clinical trials, we offer clinical trial options to patients across several locations within AON’s network of oncology practices.

Clinical Trial researcher placing test tube in holder.

Why participate in clinical trials?

Clinical trials are designed to evaluate the effectiveness of new treatment interventions. The objective of these clinical trials is to test new therapies in patients who have cancer. Patients participate in clinical trials for several reasons, including:

  • The potential to benefit from a new drug or treatment procedure
  • Improved management of symptoms resulting from treatment of cancer
  • The opportunity to directly contribute to improving the understanding of how to treat a cancer and ultimately, benefit other patients

Patients who participate in clinical trials receive either a promising new treatment or the best available conventional treatment. If a new treatment option is proven to work, patients who are participating in the clinical trial will be among the first to benefit. While there is no guarantee that any treatment will be successful, clinical trials have been proven to offer some of the most effective cancer treatments currently available today.

Talk to your doctor to discuss your clinical trial options.

Search for a Clinical Trial

Cancer Type

Practice

Line of Therapy

20-041-NCP BESPOKE

Colon and Rectal Cancer

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

MORE DETAILS
20140346 RECITE

Colon and Rectal Cancer, Pancreatic Cancer, Hematology and Blood Disorders

A phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer

MORE DETAILS
20170543 CodeBreak 100

Biliary Cancer, Brain Cancer, Breast Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Melanoma, Ovarian and Endometrial Cancer, Pancreatic Cancer, Prostate Cancer

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)

MORE DETAILS
20170770 PROCLAIM

Breast Cancer, Lung Cancer, Hematology and Blood Disorders, Ovarian and Endometrial Cancer

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

MORE DETAILS
2018-01

Breast Cancer, Lung Cancer, Colon and Rectal Cancer, Prostate Cancer, Bladder Cancer, Kidney Cancer, Pancreatic Cancer, Liver Cancer, Ovarian and Endometrial Cancer

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

MORE DETAILS
2018-01B

Breast Cancer, Lung Cancer, Colon and Rectal Cancer, Prostate Cancer, Bladder Cancer, Ovarian and Endometrial Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer

Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: "Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

MORE DETAILS
2019-013-GLOB1 (GI 301) FRESCO-2

Colon and Rectal Cancer

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer

MORE DETAILS
2020-013-00US3368 (BRE 368)

Breast Cancer

An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Triple Negative Breast Cancer

MORE DETAILS
61186372EDI1001 CHRYSALIS

Lung Cancer

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

MORE DETAILS